These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2104664)

  • 1. Leukemia following chemotherapy for ovarian cancer.
    Kaldor JM; Day NE; Pettersson F; Clarke EA; Pedersen D; Mehnert W; Bell J; Høst H; Prior P; Karjalainen S
    N Engl J Med; 1990 Jan; 322(1):1-6. PubMed ID: 2104664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemia following Hodgkin's disease.
    Kaldor JM; Day NE; Clarke EA; Van Leeuwen FE; Henry-Amar M; Fiorentino MV; Bell J; Pedersen D; Band P; Assouline D
    N Engl J Med; 1990 Jan; 322(1):7-13. PubMed ID: 2403650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.
    Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M
    N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute leukemia after alkylating-agent therapy of ovarian cancer.
    Reimer RR; Hoover R; Fraumeni JF; Young RC
    N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
    Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN
    N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
    Petru E; Schmähl D
    Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia following chemotherapy for breast cancer.
    Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
    Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms.
    Mehnert WH; Haas JF; Kittelmann B; Staneczek W; Möhner M; Kaldor JM; Day NE
    IARC Sci Publ; 1986; (78):203-21. PubMed ID: 3583391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
    Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
    N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The risk of the occurrence of acute nonlymphoblastic leukemia in patients with malignant neoplasms undergoing radio- and chemotherapy].
    Arkad'eva MA; Zaridze DG
    Vopr Onkol; 1991; 37(11-12):1086-90. PubMed ID: 1669202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.